Navigation Links
CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
Date:4/27/2009

Technology also has potential to fight cancer, rheumatoid arthritis, as well as enhance the effectiveness of vaccines

VIENNA, Va., April 27 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today the presentation of data at the 11th annual National Foundation of Infectious Diseases Conference in Baltimore which demonstrates how vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology can induce protection against infectious disease, induce immunity against HIV, and promote immunotherapy for rheumatoid arthritis. The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy and colleagues showed that CEL-SCI's L.E.A.P.S. vaccines can activate and cause human blood monocyte cells to become dendritic cells that secrete the IL-12 cytokine. The dendritic cells that result initiate a protective cell mediated and antibody immune response. These results were obtained for L.E.A.P.S. vaccines against HSV and HIV. The use of the L.E.A.P.S. vaccine technology may thus open a whole new way of maturing dendritic cell vaccines for infectious diseases such as pandemic flu and cancer.

Dr. Rosenthal reported that within three days of treatment with either the anti-HSV or the anti-HIV L.E.A.P.S. vaccine, human blood cell monocytes purified from several different donors became mature dendritic cells. The transition was indicated by the expression of cell surface proteins, cell appearance and production of IL-12. Unlike monocytes treated with other matur
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... PARK, Calif. , April 30, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... results on Thursday, May 7, 2015 after the close ... a conference call and webcast on Thursday, May 7, ... to discuss the results and recent corporate developments. ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
(Date:4/29/2015)... According to a new market research report “Vibration ... Component (Accelerometer, Proximity Probe, & Others), Application (Aerospace ... Others), & Geography - Global Forecast to 2020", ... Million by 2020, at a CAGR of 6.6%. ... figures spread through 205 pages and in-depth TOC ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... study of single-agent carfilzomib, a next generation proteasome inhibitor, ... achieved an overall response rate (ORR) (partial response or ... response (DOR) of 8.3 months in patients who entered ...
... show scientists the way to make batches of nanotubes of ... Physical Review Letters unveils an elegant formula by ... the energy of a piece of graphene cut at any ... materials science and of chemistry, said this alone is significant ...
... 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... the first 60 patients enrolled in the Phase I/II trial ... reported today in an oral presentation at the 52nd American ... Florida. "Anemia is the most serious symptom associated ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 2Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 3Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 4Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 5Pure nanotube-type growth edges toward the possible 2Pure nanotube-type growth edges toward the possible 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... human chromosome 17 and mouse chromosome 11 offers unique ... mammals, said a Baylor College of Medicine researcher who ... the journal Nature. , The work represents the first ... and annotated, said Dr. James R. Lupski, vice chair ...
... at Uppsala University, Sweden has shown in a new study, ... the spot on a male collared flycatcher's forehead reflects how ... influenza. The white spot is also attractive to female birds ... attempted to explain why individuals of a species differ in ...
... action how the "hot" emotional centers of the brain ... involved in memory tasks. Their functional magnetic resonance imaging ... revealed a "see-saw" effect, in which activation of emotional ... such processing. , The findings of the Duke University ...
Cached Biology News:Mouse to man: The story of chromosomes 2Attractive birds more immune against bird flu 2How 'hot' emotional brain interferes with 'cool' processing 2How 'hot' emotional brain interferes with 'cool' processing 3How 'hot' emotional brain interferes with 'cool' processing 4
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Biology Products: